OSL:CRNA - NO0013033795 - Common Stock
The current stock price of CRNA.OL is 0.606 NOK. In the past month the price decreased by -3.5%. In the past year, price decreased by -45.65%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 20 | 319.75B | ||
AMG.DE | AMGEN INC | 12.9 | 129.53B | ||
GIS.DE | GILEAD SCIENCES INC | 14.8 | 121.55B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 23.26 | 86.34B | ||
ARGX.BR | ARGENX SE | 87.74 | 39.68B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.35B | ||
IDP.DE | BIOGEN INC | 8.88 | 17.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.26B | ||
0QF.DE | MODERNA INC | N/A | 8.05B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 7.29B | ||
ABVX.PA | ABIVAX SA | N/A | 5.69B | ||
1VKTX.MI | VIKING THERAPEUTICS INC | N/A | 2.59B |
Circio Holding ASA is a biotechnology company, which engages in developing novel circular RNA and immunotherapy medicines. The company is headquartered in Lysaker, Akershus. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
CIRCIO HOLDING
Vollsveien 19
Lysaker AKERSHUS NO
Employees: 9
Phone: 4721398810
The current stock price of CRNA.OL is 0.606 NOK. The price increased by 0.66% in the last trading session.
The exchange symbol of CIRCIO HOLDING is CRNA and it is listed on the Euronext Oslo exchange.
CRNA.OL stock is listed on the Euronext Oslo exchange.
7 analysts have analysed CRNA.OL and the average price target is 3.06 NOK. This implies a price increase of 404.95% is expected in the next year compared to the current price of 0.606. Check the CIRCIO HOLDING stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CIRCIO HOLDING (CRNA.OL) has a market capitalization of 63.94M NOK. This makes CRNA.OL a Micro Cap stock.
CIRCIO HOLDING (CRNA.OL) currently has 9 employees.
CIRCIO HOLDING (CRNA.OL) has a support level at 0.59 and a resistance level at 0.61. Check the full technical report for a detailed analysis of CRNA.OL support and resistance levels.
The Revenue of CIRCIO HOLDING (CRNA.OL) is expected to decline by -25.6% in the next year. Check the estimates tab for more information on the CRNA.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRNA.OL does not pay a dividend.
The PE ratio for CIRCIO HOLDING (CRNA.OL) is 0.22. This is based on the reported non-GAAP earnings per share of 2.79 and the current share price of 0.606 NOK. Check the full fundamental report for a full analysis of the valuation metrics for CRNA.OL.
ChartMill assigns a fundamental rating of 2 / 10 to CRNA.OL. CRNA.OL may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months CRNA.OL reported a non-GAAP Earnings per Share(EPS) of 2.79. The EPS increased by 117.43% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | 451.2% | ||
ROE | N/A | ||
Debt/Equity | N/A |
7 analysts have analysed CRNA.OL and the average price target is 3.06 NOK. This implies a price increase of 404.95% is expected in the next year compared to the current price of 0.606.
For the next year, analysts expect an EPS growth of -183.35% and a revenue growth -25.6% for CRNA.OL